Biotechnology company Flagship Pioneering has unveiled its generative AI platform Expedition Medicines, backed by $50 million in funding.  Flagship believes Expedition Medicines will push the boundaries in medicine to enable the creation of first-in-class therapies across oncology, immunology and other diseases. The platform can learn the rules of molecular reactivity to generate small molecule drugs […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!